BioSpace News Archive

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 – a differentiated Kv7 potassium channel modulator – administered as adjunctive treatment in adult patients with focal epilepsy.

Compugen Ltd. (NASDAQ: CGEN), today announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.

Lyra Therapeutics, Inc. announced that new, positive LYR-210 data from the LANTERN 6-month post-treatment evaluation and recently completed pharmacokinetic study, were the subject of two oral presentations at the 67th Annual Meeting of the American Rhinologic Society on October 1-2.

Protagonist Therapeutics, Inc. announced that an abstract highlighting new results from its Phase 2 study of rusfertide in hereditary hemochromatosis has been selected for oral presentation at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases, taking place virtually November 12-15, 2021.

Xencor, Inc. today announced an exclusive collaboration and worldwide license agreement with Janssen Biotech, Inc. to develop and commercialize plamotamab and novel XmAb® B-cell targeting bispecific antibodies that are designed to conditionally activate T cells through the CD28 co-stimulatory receptor.

AlloVir, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to posoleucel (Viralym-M, ALVR105) for the treatment of virus-associated hemorrhagic cystitis (HC).

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens

SAB Biotherapeutics today announced that the first patient has been dosed with SAB-185 in the Phase 3 ACTIV-2 COVID-19 trial.

Adamis Pharmaceuticals Corporation announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s board of directors.

OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that it has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the Acuitas® AMR Gene Panel, and is finalizing preparations for its swift commercial launch in the U.S.